ACCREDITATION AND CREDIT DESIGNATION
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professions Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
Identify key toxicities of CAR T-cell therapy, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS);
Summarize therapeutic applications of cellular and gene therapies in classical hematology;
Explain the immunologic and cellular pathways contributing to CAR T-cell–related toxicities;
Compare existing cellular therapy strategies and their limitations in treating solid tumors;
Discuss logistical and financial challenges impacting cellular and gene therapy access in hematologic diseases;
Analyze novel antigen targets and therapeutic constructs for cellular therapy in solid tumor malignancies;
Evaluate clinical and biological barriers to implementing CAR T-cell therapy in myeloid malignancies;
Assess the translational potential of emerging cellular therapy strategies for hematologic and solid tumor indications.
TARGET AUDIENCE
This activity is designed for basic and translational researchers, hematology and medical oncology physicians and fellows, immunologists, and other healthcare professionals interested in tumor immunology and cellular immunotherapy.